| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -4,540 | -4,860 | -5,420 | -5,110 | 670 |
| Net Income Growth | +6.58% | +10.33% | -6.07% | -862.69% | +115.84% |
Cero Terapeutics Hldg Inc (CERO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
CERo Therapeutics Holdings Inc. is an immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. The company's lead product candidate includes CER-1236. CERo Therapeutics Holdings Inc., formerly known as Phoenix Biotech Acquisition Corp., is based in OAKLAND, Calif.
Fiscal Year End Date: 12/31